Saturday, February 10, 2018 2:30:53 AM
Some companies cash rich have that cash burning in their pockets.
Cannot wait to go out and buy a potential pipeline.
Of those companies mentioned in your post, it is almost as though the buyers are so laden with cash, to them it is like buying a lotto ticket.
As pointed out in your post N2K, many of those purchases do not pan out for one reason or another. And still other acquisitions just continue to burn cash.
Elite has two platforms which are cash rich pipelines for any company
seeking them as a buyout.
The ADF technology is pretty much in demand right now. Once SequestOx is green lighted it will be off to the races trying to keep up with demand.
The other technology, a partnership, between Elite and SunGen will have its own market for any solid dose form. We have seen the BE trials for two such drugs and both met top line results. One of these drugs is now a submitted ANDA. The other is in the queue waiting for its ANDA submission.
As one can see from your posting, there are quite a few miffs by big pharma when it comes to buying promising companies and their pipelines.
Elite will not be one of those mistakes. NH knows this, and so do savvy Elite share holders.
Cannot wait to go out and buy a potential pipeline.
Of those companies mentioned in your post, it is almost as though the buyers are so laden with cash, to them it is like buying a lotto ticket.
As pointed out in your post N2K, many of those purchases do not pan out for one reason or another. And still other acquisitions just continue to burn cash.
Elite has two platforms which are cash rich pipelines for any company
seeking them as a buyout.
The ADF technology is pretty much in demand right now. Once SequestOx is green lighted it will be off to the races trying to keep up with demand.
The other technology, a partnership, between Elite and SunGen will have its own market for any solid dose form. We have seen the BE trials for two such drugs and both met top line results. One of these drugs is now a submitted ANDA. The other is in the queue waiting for its ANDA submission.
As one can see from your posting, there are quite a few miffs by big pharma when it comes to buying promising companies and their pipelines.
Elite will not be one of those mistakes. NH knows this, and so do savvy Elite share holders.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
